VIVIMEDLAB.NS stock pre-market 07 Jan 2026: **489.58x** volume spike signals interest
A sharp pre-market volume surge flagged VIVIMEDLAB.NS stock on 07 Jan 2026 as volume jumped to 33,907 shares versus an average of 4,974, a 489.58x relative volume. The surge arrives with the NSE price at INR 13.61 and year high INR 29.40. Traders should note liquidity returned ahead of regular hours, with technical indicators and company fundamentals pointing to mixed risk-reward for short-term trading or hold strategies.
Pre-market volume spike snapshot for VIVIMEDLAB.NS stock
Volume readings show 33,907 traded in pre-market on 07 Jan 2026 against an average of 4,974. Relative volume is 489.58, indicating active participation and easier order execution. The immediate price on NSE is INR 13.61, unchanged from the prior close, so the spike is liquidity-driven rather than price-driven.
Price, valuation and key metrics for VIVIMEDLAB.NS stock
Vivimed Labs trades at INR 13.61 on the NSE with market cap INR 1,015,695,275.00 and 82,913,900 shares outstanding. The trailing PE is -4.18 and EPS is -2.93, reflecting recent losses. The 50-day average price is INR 8.61 and the 200-day average is INR 5.86, both below current price.
Technical read: momentum and trend after the volume spike
Trend indicators show ADX 61.02, suggesting a strong trend while RSI stands at 50.73, near neutral. Money flow (MFI) is 77.97, pointing to short-term buying pressure. Traders should watch MACD histogram at -0.61 for a crossover signal before assuming continuation.
Fundamentals and sector context for VIVIMEDLAB.NS stock
Vivimed Labs operates in Healthcare, specifically Drug Manufacturers – Specialty & Generic. The healthcare sector YTD performance is -5.95%, offering limited tailwinds. The company reports a current ratio of 0.80 and debt-to-market-cap of 3.71, reflecting liquidity strain and leverage risk relative to peers.
Meyka grade and technical commentary on VIVIMEDLAB.NS stock
Meyka AI rates VIVIMEDLAB.NS with a score of 46 out of 100 (C+) — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score reflects negative EPS, stretched working capital, and recent volume interest that improves tradability but not fundamentals.
Trading implications and short-term strategy for VIVIMEDLAB.NS stock
Volume spike increases liquidity and lowers execution risk in the pre-market. For short-term traders, a confirmed close above INR 15.00 with continued volume could validate a momentum trade. For investors, fundamentals and low current ratio argue for selective exposure and position sizing discipline.
Final Thoughts
Key takeaways: VIVIMEDLAB.NS stock shows a 489.58x pre-market volume spike on 07 Jan 2026, with price at INR 13.61 on the NSE and market cap INR 1,015,695,275.00. Technicals are mixed: ADX 61.02 signals a trend, RSI 50.73 is neutral, and MFI 77.97 points to buying pressure. Meyka AI’s model projects a monthly figure of INR 63.98, implying upside of 370.02% versus the current price, but this is a model-based projection and not a guarantee. Short-term traders can use the volume spike for entries if price action confirms momentum above INR 15.00. Investors should weigh negative EPS -2.93, PE -4.18, and weak liquidity ratios before adding exposure. For a balanced approach, limit allocation and set stop-losses near recent support levels. Meyka AI provides this analysis as an AI-powered market analysis platform and not investment advice.
FAQs
The pre-market spike to **33,907** shares on 07 Jan 2026 raised relative volume to **489.58x**. The move appears liquidity-driven, with no immediate price-moving corporate news. Watch for confirmation in regular hours and SEC filings for fresh catalysts.
Meyka AI’s forecast model projects a monthly figure of **INR 63.98**, comparing to the current **INR 13.61**. This implies model-based upside of **370.02%**, which investors should treat as a high-variance projection, not a guarantee.
The spike improves tradability but fundamentals remain mixed. Meyka AI assigns a **C+ (HOLD)** grade. Short-term trades can follow momentum, while longer-term investors should wait for margin improvement and stronger liquidity metrics.
Traders should watch resistance near **INR 15.00** and support near the pre-spike level at **INR 13.61**. A sustained close above **INR 15.00** with volume would favour momentum continuation.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.